TWI770595B - Use of lactic acid bacteria for the treatment or prevention of liver damage-related diseases - Google Patents

Abstract

The present invention discloses the use of a lactic acid bacterium for treating or preventing liver damage-related diseases. Specifically, the lactic acid bacterium comprises Pediococcus pentosaceus TTL 3-14 and/or Lactobacillus paracasei subsp. Lactobacillus paracasei subsp . paracasei) TTL 6-2, and when an effective amount of the novel lactic acid bacteria disclosed in the present invention is administered to an individual, it can effectively achieve the effect of treating or/and preventing alcohol-induced liver damage or fatty liver.

Description

Use of lactic acid bacteria for the treatment or prevention of liver damage-related diseases

The present invention relates to probiotics and their uses, in particular to the use of a lactic acid bacteria for treating or preventing liver damage-related diseases.

The liver is a very important part of the human digestive system, with functions such as absorption, metabolism and immune protection. Long-term and chronic drinking behavior will affect the body's metabolism, causing triglycerides and cholesterol to accumulate in the liver, resulting in fatty liver or other alcoholic liver diseases. Specifically, according to studies, the metabolite of alcohol, ethanol, can change the permeability of intestinal epithelial cells, increase the production of bacterial toxins in the intestine, such as endotoxin, and then induce or aggravate liver disease.

In addition, although fatty liver does not cause immediate harm to human health, it will damage liver cells in the long run, and cause irreversible diseases such as hepatitis, liver fibrosis, liver cirrhosis or liver cancer. Drugs for the treatment of fatty liver can only control or improve fatty liver or its related metabolic diseases through changes in eating habits and living habits. However, the vast majority of patients cannot change their life or eating habits for a long time, resulting in the clinical manifestation of fatty liver. The above treatment is difficult.

Therefore, the development of a composition that can effectively treat or prevent liver damage-related diseases is a top priority of current medical research.

The main purpose of the present invention is to provide a second use of lactic acid bacteria, wherein the lactic acid bacteria are Pediococcus pentosaceus TTL 3-14, or Lactobacillus paracasei subsp . paracasei TTL 6-2; and the lactic acid bacteria have the ability to increase the activity of liver antioxidant enzymes and reduce inflammatory factors, so as to effectively prevent or improve liver cell damage or related diseases, especially liver diseases caused by alcohol, such as fatty liver.

Specifically, Pediococcus pentosaceus TTL 3-14, the deposit number is BCRC 911008, the deposit date is July 13, 2020, and the deposit place is at the Biological Resource Conservation and Research Center, Hsinchu Food Industry Development Institute, Taiwan; Lactobacillus paracasei subsp.paracasei TTL 6-2, the deposit number is BCRC 911009, the deposit date is July 13, 2020, and the deposit place is at the Biological Resource Conservation and Research Institute of Hsinchu Food Industry Development Institute, Taiwan. Research center.

Another object of the present invention is to provide a composition comprising an effective amount of the lactic acid bacteria disclosed in the present invention, and by administering the composition to an individual, it can effectively improve or prevent liver damage, fatty liver or other related diseases Diseases related to the above symptoms.

Specifically, the composition disclosed in one embodiment of the present invention contains at least one lactic acid bacteria, and the lactic acid bacteria is Pediococcus pentosaceus TTL 3-14 or Lactobacillus paracasei subsp. paracasei TTL 6 -2.

In order to achieve better liver disease prevention or/and treatment efficacy, in another embodiment of the present invention, the composition comprises Pediococcus pentosaceus TTL 3-14 and Lactobacillus paracasei subsp. paracasei TTL 6 -2.

Furthermore, in another embodiment of the present invention, the composition comprises another lactic acid bacteria, which is Lactobacillus plantarum TTL 8-16; preferably, the composition is composed of Pediococcus pentosaceus TTL 3 -14. Lactobacillus paracasei subsp. paracasei TTL 6-2 and Lactobacillus plantarum plant subsp. TTL 8-16 are mixed in equal weight ratios.

In the embodiment of the present invention, the composition can be prepared as a food or a nutritional supplement, and can be prepared into different dosage forms, such as powder, lozenge, etc., according to requirements.

In another embodiment of the present invention, the use of the lactic acid bacteria disclosed in the present invention for treating or preventing liver damage-related diseases is disclosed, that is, when an effective amount of the novel lactic acid bacteria disclosed in the present invention or a composition containing the same is administered to an individual It can effectively achieve the effect of preventing or/and treating alcoholic liver injury or its related diseases.

Among them, the alcoholic liver injury is fatty liver.

Among them, the composition is a hepatic antioxidant enzyme activity promoter, which can enhance the activities of glutathione and glutathione peroxidase, and strengthen the antioxidant capacity of the liver, so as to avoid or improve the damage of liver tissue. effect.

Figure 1 shows the relative clearance rates of AST detected and analyzed by HepG2 cells in each group after different treatments.

Figure 2 shows the relative clearance rate of ALT detected and analyzed after different treatments of HepG2 cells in each group.

Figure 3 shows the results of recording the body weight changes of mice in each group at the 0th, 2nd, 4th, 6th and 8th weeks of the experiment.

Figure 4 shows the results of recording the AST activity in the serum of each group of mice at the 0th, 2nd, 4th, 6th and 8th weeks of the experiment.

Figure 5 shows the results of recording the ALT activity in the serum of each group of mice at the 0th, 2nd, 4th, 6th and 8th week of the experiment.

Figure 6 shows the results of recording the serum cholesterol levels of mice in each group at the 0th, 2nd, 4th, 6th, and 8th weeks of the experiment.

Figure 7 shows the results of recording triglyceride levels in serum of mice in each group at 0, 2, 4, 6, and 8 weeks of the experiment.

Figure 8 shows the results of detecting the content of triglycerides in the livers of mice in each group.

Figure 9 shows the results of detecting glutathione activity in the livers of mice in each group.

Figure 10 shows the results of detecting glutathione peroxidase activity in the livers of mice in each group.

Figure 11 shows the results of H&E staining of the liver tissue sections of mice in the first group.

Figure 12 shows the results of H&E staining of the second group of mouse liver tissue sections.

Figure 13 shows the results of H&E staining of the third group of mouse liver tissue sections.

Figure 14 shows the results of H&E staining of the liver tissue sections of mice in the fourth group.

Figure 15 shows the results of H&E staining of the liver tissue sections of mice in the fifth group.

Figure 16 shows the results of H&E staining of the liver tissue sections of mice in the sixth group.

The lactic acid bacteria disclosed in the present invention, including strain TTL 3-14 and strain TTL 6-2, are isolated from cereal sources and have the basic characteristics of probiotics, such as acid resistance, bile salt resistance, and intestinal epithelial cell adhesion, etc. Harmful organisms; of which: the deposit number of strain TTL 3-14 is BCRC 911008, the deposit date is July 13, 2020, and the deposit place is at the Biological Resource Conservation and Research Center, Hsinchu Food Industry Development Institute, Taiwan; and strain TTL 3 -14 is a gram-positive coccus with no catalase, oxidase and motility properties, does not produce endospores, and can grow under both aerobic and anaerobic conditions.

The deposit number of the strain TTL 6-2 is BCRC 911009, the deposit date is July 13, 2020, and the deposit place is at the Biological Resource Conservation and Research Center, Hsinchu Food Industry Development Institute, Taiwan; while the strain TTL 6-2 is Gram-positive Bacillus has no catalase, oxidase and motility properties, does not produce endospores, and can grow under both aerobic and anaerobic conditions.

The strains TTL 3-14 and TTL 6-2 disclosed in the present invention can be cultivated in the following conditions: the culture medium is a lactic acid bacteria MRS medium (Lactobacilli MRS broth, BD, 0.05% L-cysteine) containing 0.05% L-cysteine. difco, USA), cultured at 37°C for 16 hours; the storage conditions after culture were as follows: MRS broth (MRS broth) containing 15% glycerol, at -80°C.

The "strain TTL 3-14" referred to in the present invention is Pediococcus pentosaceus Pediococcus pentosaceus TTL 3-14 with accession number BCRC 911008.

The "strain TTL 6-2" referred to in the present invention is Lactobacillus paracasei subsp . paracasei TTL 6-2 with accession number BCRC 911009.

The "strain TTL 8-16" referred to in the present invention is Lactobacillus plantarum subsp . plantarum TTL 8-16 with deposit number BCRC 910871, deposited on February 15, 2019, and deposited in Taiwan Bioresource Conservation and Research Center, Hsinchu Food Industry Development Institute; further, TTL 8-16 strains are Gram-positive bacilli, without catalase, oxidase and motility, and do not produce endospores. Can grow in anaerobic conditions.

The term "lactide bacteria composition" in the present invention refers to mixing the cultured strains TTL 3-14, strains TTL 6-2 and strains TTL 8-16 in an equal weight ratio (1:1:1) or, wherein, each strain should be washed with sterile phosphate buffer before mixing.

The term "effective amount" in the present invention refers to the amount of the compound or active ingredient required to produce the desired specific effect, expressed as a percentage by weight in the composition. As is understood by those of ordinary skill in the art to which this invention pertains, the effective amount will vary depending on the manner of administration intended to elicit the particular effect. Generally, the active ingredient or compound can be present in the composition in an amount from about 1% to about 100%, preferably from about 30% to about 100%, by weight of the composition.

Hereinafter, in order to further illustrate the technical features and effects of the present invention, a number of examples will be given and illustrated in detail as follows.

The strains used in the following examples were stored in MRS broth containing 15% glycerol at -80°C. The strain was activated twice, the medium was Lactobacilli MRS broth (BD, difco, USA) containing 0.05% L-cysteine, and the culture condition was 37° C. for 24 hours.

The human hepatoma cell C3A (HepG2/C3A) (Accession No.: BCRC 60177) and mouse macrophage RAW264.7 (Accession No.: BCRC 60001) used in the following examples were purchased from the Institute of Food Industry Bioresources and Research Center (Taiwan).

Example 1: In vitro anti-inflammatory test

Human hepatoma cells C3A (hereafter referred to as HepG2 cells) and mouse macrophage RAW264.7 (hereafter referred to as RAW264.7 cells) were cultured in 24-well plates, and the number of HepG2 cells in each well was 2 x 105 cells/ The cell volume of well and RAW264.7 cells is 1 x 105 cells/well. When the cells grow to 80%, they are washed with phosphate buffered saline, respectively, and then new medium is added, and then 100 μl of endotoxin lipopolysaccharide (LPS, 100ng/well) is added. mL) and 100 μl of lactic acid bacteria liquid, the number of bacteria is 109CFU/mL, and then cultured in a carbon dioxide incubator for 24 hours, and the cell supernatant of each well was collected.

The supernatant collected from RAW264.7 cells was used to detect the content of TNF-α and IL-6 with a commercially available Enzyme-linked immunosorbent assay kit ELISA, purchased from BioLegend; and collected from HepG2 cells The supernatant was obtained by using a commercially available enzyme-linked immunoassay kit (BD OptEIA Set Human IL-8, purchased from BD Biosciences) to detect the content of IL-8. The results are shown in Table 1 below, wherein the blank group was not added LPS and lactic acid bacteria liquid, LPS group was not added lactic acid bacteria liquid.

From the results in Table 1, it can be seen that strain TTL 3-14, strain TTL 6-2 and strain TTL 8-16 can reduce TNF-α and IL-6, but for Hep G2 cells stimulated by LPS to produce inflammatory hormone: IL-8 For example, only strain TTL 3-14 and strain TTL 6-2 can achieve significantly better inhibitory effect.

Since Hep G2 cells do not produce inflammatory factors such as IL-6, TNF-α, and IFN-γ after being stimulated by LPS, they will significantly produce IL-8. Therefore, it can be clearly seen from Table 1 above that the disclosed Strain TTL 3-14 and strain TTL 6-2 can not only inhibit inflammation in the body, but also have good therapeutic or preventive effects on liver inflammation.

Example 2: In vitro alcohol tolerance test

Take strain TTL 3-14, strain TTL 6-2, strain TTL 8-16 respectively, cultivate for 16 hours after activation, and then take 100 μl of the cultured bacterial liquid and inoculate into 4 mL MRS medium (MRS broth) without alcohol, respectively. In 4 mL of MRS medium containing final alcohol concentration of 1%, 5%, 10%, 15% and 20%, cultured at 37°C for 16 hours, and then serially diluted the cultured bacterial solution and counted by plate count The number of bacteria, the results are shown in Table 2 below.

As can be seen from the results of the above table 2, the strains TTL 3-14 and the strain TTL 6-2 disclosed by the present invention can survive in the environment of high concentration alcohol, and wherein, the tolerance of the strain TTL 6-2 to alcohol is relatively high. Good, which means that it can survive in an environment containing more than 20% alcohol.

Example 3: Detection of biochemical indicators of alcoholic liver injury in vitro

HepG2 cells were seeded into a 24-well plate at 2 x 105 cells/well. When the cells grew to 80%, they were washed with phosphate buffered saline, and then the medium was changed to MEM medium without FBS, and grouped by different conditions. Treatment, wherein: blank group added 1ml medium; alcohol group added 900μl medium; The silymarin (SML) group was added with 800 μl of medium, 100 μl of alcohol, the final concentration of alcohol was 100 mM, and then 100 μl of silymarin (30 μg/mL) was added; each strain group was added with 800 μl of medium, 100 μl of alcohol was added, and the final concentration of alcohol was 100 mM, and then Lactic acid bacteria solution was added; after each group was placed for 24 hours, the supernatant and cells were collected, and the commercially available ALT analysis kit (purchased from BioVision) and AST analysis kit (purchased from BioVision) were used to detect aspartate aminotransferase (hereinafter referred to as AST). ) and alanine aminotransferase (hereinafter referred to as ALT) content, the results are shown in Figure 1 and Figure 2.

It can be seen from the results of Fig. 1 and Fig. 2 that when HepG2 cells are stimulated by alcohol to produce ALT and AST, only the strains TTL 3-14 and TTL 6-2 disclosed in the present invention can reduce the content of ALT and AST at the same time. The strain TTL 3-14 and the strain TTL 6-2 disclosed in the present invention have the effect of protecting the liver from being stimulated by alcohol and causing inflammation or pathological changes.

Example 4: Detection of serum biochemical indicators

60 seven-week-old C57BL/6N male mice (Lesco Bio, Taiwan) were purchased and raised in an environment with a temperature of 22 ± 2 °C, a relative humidity of 55 ± 5%, and a light cycle period of 12 hours. The feed used is liquid general feed.

After the mice were reared for 1 week, they were randomly divided into groups, and each group was reared for 8 weeks under the following treatment conditions, and the mice in each group were sacrificed after the experiment was completed, and their livers were taken separately to carry out the experiments of the following examples: Group 1 (Blank group): only fed with liquid general diet without alcohol; Group 2 (alcohol group): fed with liquid alcohol diet with total calorie 36% alcohol (0.36kcal/ml); Group 3 (strain TTL 3-14 Group): fed a liquid alcohol diet containing 36% alcohol (0.36kcal/ml) in total calories and strain TTL 3-14 at a dose of 9 log CFU/ml; Group 4 (strain TTL 6-2 group): fed a liquid alcohol diet with total calorie 36% alcohol (0.36kcal/ml) and strain TTL 6-2 at a dose of 9 log CFU/ml; group 5 (strain TTL 8 -16 groups) were fed a liquid alcohol diet with a total calorie of 36% alcohol (0.36kcal/ml) and strains TTL 8-16 at a dose of 9 log CFU/ml; group 6 (lactic acid bacteria composition group) was fed with a total calorie of 36% alcohol (0.36kcal/ml) of the liquid alcohol feed and the lactic acid bacteria composition at a dose of 9 log CFU/ml each.

The mice in each group were recorded body weight and blood was collected from the eye socket at 0, 2, 4, 6, and 8 weeks. The collected blood was tested for serum, and the contents of AST, ALT, triglyceride and total cholesterol were analyzed. The results are shown in the figure. 3 to Figure 7.

It can be seen from the results in Figure 3 that during the test period, the mice in each group had a normal diet, and the weight of the mice in the first group that was not fed alcohol was heavier than that of the mice in the other groups (P<0.05), indicating that long-term feeding of alcohol does induce Mice develop alcoholic hepatitis or related symptoms, resulting in decreased body weight in mice fed alcohol.

Furthermore, from the results of Figure 4 and Figure 5, it can be seen that the AST and ALT values in the serum of the mice in the first group did not change during the test period; the AST and ALT values in the serum of the mice in the second group changed with the time of alcohol feeding. Compared with the mice in the first group, the AST in the serum of the mice in the second group was significantly increased by 53% at the 8th week of the experiment; At the 8th week of the experiment, the AST values in the serum of the mice in the 3rd, 4th and 6th groups were significantly lower than those of the 2nd group, decreased by 42%, 33% and 37% respectively (P<0.05), and , the ALT values in the serum of the mice in the third and sixth groups were significantly lower than those in the second group, decreased by 54% and 48%, respectively (P<0.05). According to the research, it is pointed out that the increase of AST and ALT values in serum indicates that the liver damage is more serious. Therefore, the results of Fig. 4 and Fig. 5 show that the strains TTL 3-14 and/or strains TTL 6-2 disclosed in the present invention have It has a specific therapeutic or preventive effect on liver damage or liver disease caused by alcohol, which means administering an effective amount of the strain TTL 3-14 and/or strain TTL 6-2 disclosed in the present invention to the test subject with drinking habit In other cases, it can effectively improve or prevent alcohol-induced liver damage or liver disease.

In addition, although it can be seen from the results in Figure 6 that the total cholesterol content in the serum of the mice in each group did not change significantly, it can be seen from the results in Figure 7 that at the 4th week of the experiment, compared with the mice in the second group, the mice in the third group had higher levels of cholesterol. and the 4th group of mice serum triglyceride content was significantly reduced (P<0.05), decreased by 28.9 and 22.7%, and the effect of the decrease could be maintained until the end of the test (the 8th week); further, At the 4th week of the experiment, the serum triglyceride content of mice in group 5 decreased the best, which was about 44.8% lower than that of mice in groups 3 or 4, while the serum content of mice in group 6 decreased by about 44.8%. The triglyceride content decreased by about 23.9%; after the 4th week of the experiment, except for the second group of mice, the serum triglyceride content of the mice in each group was almost the same as that of the first group (blank group) mice. At the 8th week of the experiment, the triglyceride content in the serum of the mice in the 5th and 6th groups continued to decrease, which was about 35.4% and 34.4% lower than the triglyceride in the serum of the mice in the second group, respectively. %, there was a significant difference between them (P<0.05). In other words, the results in FIG. 7 show that the strain TTL 8-16 and/or the strain TTL 3-14 and/or the strain TTL 6-2 disclosed in the present invention can continuously and effectively reduce triacids in serum under the alcoholic diet The content of glycerides can achieve the effect of preventing or treating vascular disease caused by alcohol.

Example 5: Detection of triglyceride content in liver

Take the liver tissue of each group of mice that have completed the experiment in Example 1, and after homogenizing centrifugation, take the supernatant, add the prepared triglyceride enzyme reagent (Triglyceride Enzyme Mixture), and measure the OD530-550nm absorbance after the reaction value, subtract the OD value of the standard substance (0mg/dl) from the obtained OD value, and then calculate the triglyceride content in the liver of each group of mice through the linear regression analysis of the drawn standard curve, and the results are shown in Figure 8 shown.

From the results in Figure 8, it can be seen that compared with the mice in the first group, the content of triglycerides in the liver of the mice in the second group increased significantly after 8 weeks, which means that the alcohol diet will indeed lead to the accumulation of liver fat and induce fatty liver. Compared with the mice in group 2, the triglyceride content in the liver of mice in groups 3 to 6 decreased significantly by 49.8%, 53.7%, 45.9% and 47.2%, respectively.

From the results, it can be seen that the strain TTL 3-14 and/or the strain TTL 6-2 disclosed in the present invention can indeed avoid the accumulation of triglycerides in the liver tissue under an alcoholic diet, and if an effective amount of the present invention is continuously administered It was revealed that strains TTL 3-14 and/or strains TTL 6-2 to individuals with drinking habits were able to maintain triglyceride levels in their livers similar to those of non-drinking individuals.

Example 6: Detection of Antioxidant Enzyme Expression in Liver

The liver tissue of each group of mice that had been tested in Example 1 was taken and subjected to homogenization and centrifugation, respectively, and the supernatant was taken, and then the commercially available analysis kits (QuantiChromTM Glutathione Assay Kit and EnzyChromTM Glutathione Peroxidase Assay Kit) were used to detect each group respectively. The expression of glutathione (Glutathione, GSH) and glutathione peroxidase (Glutathione peroxidase, GPx) activities in mouse liver tissue, the results are shown in Figure 9 and Figure 10 .

From the results in Figure 9, it can be seen that after 8 weeks, the content of glutathione in the liver of the mice in the fifth group was not significantly different from that of the mice in the first group (P>0.05); the content of glutathione in the liver of the mice in the second group was significantly different. higher than that of mice in group 1 (P<0.05), but there was no significant difference between mice in group 6 (P>0.05); and compared with mice in group 2, group 3 and group 4 The content of glutathione in the liver of mice was significantly increased by 37% and 35% (P<0.05). Based on the fact that glutathione is an antioxidant substance in the organism, the results show that the strain TTL 3 disclosed in the present invention -14 and/or strain TTL 6-2 are indeed special lactic acid strains that can enhance the antioxidant capacity of the liver, which means that under alcoholic diet, the effective amount of strain TTL 3-14 and/or strain TTL 6-2 disclosed in the present invention will be When administered to an individual, it can effectively increase the glutathione in the individual's liver and achieve the effect of increasing the individual's antioxidant capacity.

Furthermore, from the results in Figure 10, it can be seen that after 8 weeks, compared with the mice in the first group, the glutathione peroxidase enzyme activity in the liver of the mice in the second group decreased by 31.9%; For group mice, although the glutathione peroxidase enzyme activity in the liver of mice in groups 3 to 6 increased (30.6%, 31.6%, 16.9% and 58.4%, respectively), the glutathione peroxidase activity in group 5 increased. The activity of glutathione peroxidase enzyme in the liver of mice is not increased to a good degree, indicating that the administration of strain TTL 8-16 has the effect of improving the antioxidant capacity of individual livers. However, administration of the strain TTL 3-14 and/or the strain TTL 6-2 disclosed in the present invention can indeed increase the glutathione peroxidase enzyme activity in the liver.

The results in Figure 9 and Figure 10 show that the strain TTL 3-14 and/or the strain TTL 6-2 disclosed in the present invention are specific lactic acid bacteria capable of enhancing the antioxidant capacity of the liver, which means that an effective amount of the strain TTL 3 is administered. -14 and/or strain TTL 6-2 to individuals with drinking habits can prevent or improve liver damage or alcohol-induced liver-related diseases by increasing the antioxidant active substances and/or antioxidant enzymes in the liver.

Example 5: Staining results of liver tissue sections

The liver tissue of each group of mice after the experiment in Example 1 was taken, embedded in paraffin and sectioned, and then stained with H&E. The results are shown in Figures 11 to 16 .

It can be seen from Figure 11 that no obvious accumulation of fatty oil droplets was found in the liver slices of the mice in the first group, and the cell nuclei were very complete; It is shown that the long-term administration of alcohol can indeed cause fat to accumulate in the liver, resulting in the symptoms of fatty liver; from the results of groups 3 to 6 shown in Figure 13 to Figure 16, it can be seen that the administration of different lactic acid bacteria or lactic acid bacteria compositions can The fat oil droplets in the liver are reduced, the accumulation of fat in the liver is reduced, and the liver cells are prevented from being destroyed, and the results of the staining of the liver tissue sections of the third group to the sixth group are compared. The strains are more effective at avoiding fat accumulation in liver tissue.

It can be seen from the above results that the strain TTL 3-14 and/or the strain TTL 6-2 disclosed in the present invention can avoid or improve the situation of fat accumulation in the liver, and can protect liver cells from damage and maintain cell integrity under alcoholic diet. In other words, when an effective amount of strain TTL 3-14 and/or strain TTL 6-2 disclosed in the present invention is administered to an individual, the effect of preventing or treating fatty liver or its related diseases can be effectively achieved.

【Biological Material Deposit】

Pediococcus pentosaceus TTL 3-14, the deposit number is BCRC 911008, the deposit date is July 13, 2020, and the deposit place is at the Biological Resource Conservation and Research Center, Hsinchu Institute of Food Industry Development, Taiwan.

Lactobacillus paracasei subsp.paracasei TTL 6-2, the deposit number is BCRC 911009, the deposit date is July 13, 2020, and the deposit place is at the Biological Resource Conservation and Development Institute of Hsinchu, Taiwan. Research center.

Lactobacillus plantarum plant subsp. TTL 8-16, deposited on February 15, 2019, with deposit number BCRC 910871.

Claims (5)

A use of lactic acid bacteria for preparing a composition for treating or/and preventing alcoholic liver injury and alcoholic fatty liver, wherein the lactic acid bacteria comprise Pediococcus pentosaceus TTL 3-14; Pediococcus pentosaceus TTL 3-14, the deposit number is BCRC 911008, the deposit date is July 13, 2020, and the deposit place is at the Biological Resource Conservation and Research Center, Hsinchu Food Industry Development Institute, Taiwan. The use according to claim 1, wherein the composition for treating or/and preventing alcoholic liver damage comprises Pediococcus pentosaceus TTL 3-14, Lactobacillus paracasei subsp. paracasei TTL 6-2 and plants Lactobacillus paracasei subsp. paracasei TTL 8-16; Lactobacillus paracasei subsp. paracasei TTL 6-2, deposit number BCRC 911009, deposited on July 13, 2020, deposited in Taiwan Biological Resource Conservation and Research Center, Hsinchu Institute of Food Industry Development; Lactobacillus plantarum plant subsp. TTL 8-16, deposit number BCRC910871, deposited on February 15, 2019, and deposited at Biotechnology, Hsinchu Institute of Food Industry Development, Taiwan Resource Conservation and Research Center. The use according to claim 2, wherein Pediococcus pentosaceus TTL 3-14, Lactobacillus paracasei subsp. TTL 6-2 and Lactobacillus plantarum TTL 8-16 are mixed in an equal weight ratio. The use according to claim 1 or 2, wherein the composition is a food or a nutritional supplement. The use according to claim 1 or 2, wherein the composition is a hepatic antioxidant enzyme activity promoter.

Images